Evaluation of Antigen-specific Th1 and Th17 Cells, ILC and MAIT in Patients With Antisynthetase Syndrome and Interstitial Lung Disease

What this Trial Is About

Researchers are investigating antisynthetase syndrome (AS), a rare autoimmune condition involving muscle inflammation and lung disease. This study focuses on patients newly diagnosed with AS and interstitial lung disease (ILD), aiming to understand how specific immune cells in the lungs relate to disease severity and treatment response over six months. The study examines immune cell types like Th1, Th17, innate lymphoid cells (ILC), and mucosal-associated invariant T cells (MAIT) that may influence disease progression. Participants will undergo testing to identify antigen-specific Th1 and Th17 cells, ILC, and MAIT cells in bronchoalveolar fluid (BAL) at the time of ILD diagnosis. This observational study does not involve experimental treatments but monitors these immune markers to assess their connection to lung disease severity. The study tracks changes in lung function and immune cell levels from diagnosis through six months of standard treatment. During the study, participants will provide samples for immune cell analysis and have lung function tests such as forced vital capacity (FVC) measured at baseline and after six months. Researchers will evaluate how initial immune cell presence correlates with changes in lung function and overall disease activity. The study lasts at least six months, with ongoing clinical assessments to monitor disease progression and response to therapy.

Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease